Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail)

v3.10.0.1
Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Accrued Expenses:    
Professional fees $ 1,471 $ 1,625
Salaries, bonuses and related benefits 4,349 5,279
Accrued expenses - related party 50 95
Research and development 3,036 1,873
Milestones related to license agreement 2,500 800
Manufacturing 1,411 1,188
Clinical supplies 2,619 85
License maintenance fees 454 100
Dr. Falk Pharma milestone (See Note 16) 1,300 3,059
Accrued royalties payable 1,045 1,411
Deferred coupon funding 1,490 1,087
Other 644 1,030
Total accrued expenses 20,369 17,632
Other long-term liabilities:    
Deferred rent and long-term lease abandonment charge 4,961 4,739
Total other long-term liabilities $ 4,961 $ 4,739